| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 15.04 | 7.4% | 11.5% |
| Total Income | 15.04 | 7.4% | 11.5% |
| Expenditure | 14.85 | 2.3% | 16.4% |
| PBT | 0.26 | 157.8% | 64.9% |
| Net Profit | 0.27 | 161.4% | 63.0% |
| OPM | 1.23% | 5.00pp | 4.20pp |
| NPM | 1.78% | 4.90pp | 3.61pp |
| EPS | 0.02 | 166.7% | 60.0% |
Champions Oncology Reports Q2 FY26 Revenue of $15.0 Million, Up 11.5%
04 May 2026 · 4 May, 6:55 am
Summary
Champions Oncology reported an 11% increase in total revenue to $15 million for the second quarter of fiscal year 2026. Oncology services profit was $7.8 million, yielding a 52% margin. Net income for the quarter was $237,000, and adjusted EBITDA was $843,000. For the first half of fiscal year 2026, total revenue increased by 5% to $29 million, with an oncology services profit of $13.8 million and adjusted EBITDA of $962,000. The company remains on track to deliver year-over-year revenue growth and achieve positive adjusted EBITDA for the full fiscal year.
Key Highlights
- 1
Total revenue increased by 11% to $15 million for the second quarter of fiscal year 2026.
- 2
Oncology services profit reached $7.8 million, resulting in an oncology services margin of 52% for Q2 FY26.
- 3
The company reported a net income of $237,000 for the second quarter of fiscal year 2026.
- 4
Adjusted EBITDA was $843,000 for the second quarter of fiscal year 2026.
- 5
Total revenue increased 5% to $29 million for the first half of fiscal year 2026.
- 6
Oncology services profit was $13.8 million, with an oncology services margin of 47% for the first half of fiscal year 2026.
- 7
Adjusted EBITDA reached $962,000 for the first half of fiscal year 2026.
Management Comments
Robert Brainin
Our recent results reinforced our confidence in the Company’s ongoing return to growth, as we continued to make progress. While our business can vary period to period, we manage and evaluate performance primarily on an annual basis and remain focused on delivering sustainable year-over-year revenue growth. We continue to be cautiously optimistic that the pharma and biotech funding environment is beginning to strengthen, which should support improved bookings as we move into calendar 2026. In parallel with our core services business, we continued to invest in our data platform—expanding its capabilities to provide greater value to our pharma partners—and strengthened our business development organization to support adoption of these offerings. As our data business scales, we expect it to contribute meaningfully to long-term growth, even as it introduces additional variability in shorter reporting periods. Together, these growth engines position Champions to create meaningful long-term value for our shareholders.
David Miller
From a financial standpoint, the period reflected continued progress in our operating model. Oncology services margin improved as higher revenue was generated on a largely stable cost base, highlighting the leverage in our business as volumes increase. Operating expenses rose as planned, reflecting targeted investments in areas that support future growth, particularly within our data platform and related infrastructure. Based on our year-to-date performance and current visibility, we remain on track to deliver year-over-year revenue growth and to achieve positive adjusted EBITDA for the full fiscal year. We believe the combination of disciplined cost control and targeted strategic investment positions the Company for continued improvement as market conditions strengthen.
Informational and educational content only. Not investment advice.